Femasys, a leader in advancing women’s reproductive healthcare, is making significant strides with groundbreaking products designed to address critical issues in fertility, cancer diagnostics, and permanent birth control. With the recent approval of its novel product, FemaSeed, by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), Femasys is poised to revolutionize the reproductive healthcare landscape.
FemaSeed offers an alternative to traditional intrauterine insemination (IUI) by directly delivering sperm into a woman’s Fallopian tubes, where fertilization typically occurs. Utilizing a unique balloon technology, FemaSeed isolates and seals the tube’s opening, allowing sperm to be directed straight into the tube. “This less invasive method is crucial at a time when sperm counts globally have dropped by more than 50% across all age groups,” said Kathy Lee-Sepsick, CEO of Femasys. The company is rapidly expanding, with two major U.S. fertility conglomerates already offering FemaSeed. To meet growing demand, Femasys has increased its manufacturing capacity and built a dedicated U.S. sales team.
Before using FemaSeed, it is essential to confirm that at least one Fallopian tube is open. Femasys addresses this need with FemVue, a diagnostic tool that uses natural saline and air contrast for ultrasound-based evaluation, a safer alternative to older methods requiring radiation. If more precise information is needed, Femasys offers FemCath, a catheter system for evaluating individual tubes.
In addition to fertility innovations, Femasys has introduced FemCerv, a new method for endocervical cancer diagnosis. FemCerv uses an expandable collection chamber that captures cervical cells and tissue during a colposcopy, offering a more comfortable and accurate alternative to traditional methods.
The company is also working on FemBloc, a non-surgical permanent birth control solution. Unlike traditional sterilization methods, FemBloc employs balloon catheters and a proprietary polymer that blocks the Fallopian tubes over time. After three months, FemChec, another Femasys product, ensures the procedure’s success by confirming the tubes are blocked through ultrasound.
With a portfolio of products available across the United States, Europe, the UK, Canada, and Israel, Femasys is at the forefront of transforming women’s healthcare. Their innovations promise to provide safer, more effective options for fertility treatment, cancer diagnostics, and birth control, offering women more control and options than ever before.
Related topics:
Couples Urged to Seek Fertility Treatment to Help Boost Birth Rate
Endometriosis Awareness Month: Expert GYN Surgeon Champions Cutting-Edge Care for Women’s Health
